CRISPR/Cas9-Based Screening of FDA-Approved Drugs for NRF2 Activation: A Novel Approach to Discover Therapeutics for Non-Alcoholic Fatty Liver Disease

With the rising prevalence of obesity, non-alcoholic fatty liver disease (NAFLD) now affects 20–25% of the global population. NAFLD, a progressive condition associated with oxidative stress, can result in cirrhosis and liver cancer in 10% and 3% of patients suffering NAFLD, respectively. Therapeutic...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, James, Arest, Sandra, Olszowy, Bartlomiej, Gordon, John, Barrero, Carlos A., Perez-Leal, Oscar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10375998/
https://www.ncbi.nlm.nih.gov/pubmed/37507903
http://dx.doi.org/10.3390/antiox12071363

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10375998/
https://www.ncbi.nlm.nih.gov/pubmed/37507903
http://dx.doi.org/10.3390/antiox12071363

Ejemplares similares